{"filing":{"accession_number":"0001776985-26-000057","cik":"0001776985","ticker":"BNTX","company_name":"BioNTech SE","form":"6-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"form6-kwclccurtainraiser20.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000057/form6-kwclccurtainraiser20.htm"},"events":[{"id":28705,"run_id":26267,"accession_number":"0001776985-26-000057","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This exhibit is a press release announcing BioNTech's presentation of clinical trial data at the WCLC 2026 conference, highlighting progress in its lung cancer pipeline including novel-novel combination trials (pumitamig + elfetabart drozuntecan), updated overall survival data for gotistobart, and mRNA-based approaches across 16 ongoing trials including five Phase 3 studies. While the disclosure concerns clinical development progress rather than a discrete event like an approval, acquisition, or financial result, it represents material operational and strategic progress in the company's core oncology development program that would affect a reasonable investor's assessment of pipeline momentum and competitive positioning.","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-20","form":"6-K","submitted_at":null,"items":[{"id":30743,"accession_number":"0001776985-26-000057","item_number":"EX-99.1","item_title":"a991260820_bntxxwclcxcurta.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a press release announcing BioNTech's presentation of clinical trial data at the WCLC 2026 conference, highlighting progress in its lung cancer pipeline including novel-novel combination trials (pumitamig + elfetabart drozuntecan), updated overall survival data for gotistobart, and mRNA-based approaches across 16 ongoing trials including five Phase 3 studies. While the disclosure concerns clinical development progress rather than a discrete event like an approval, acquisition, or financial result, it represents material operational and strategic progress in the company's core oncology development program that would affect a reasonable investor's assessment of pipeline momentum and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:37:39.162477+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30743,"accession_number":"0001776985-26-000057","item_number":"EX-99.1","item_title":"a991260820_bntxxwclcxcurta.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a press release announcing BioNTech's presentation of clinical trial data at the WCLC 2026 conference, highlighting progress in its lung cancer pipeline including novel-novel combination trials (pumitamig + elfetabart drozuntecan), updated overall survival data for gotistobart, and mRNA-based approaches across 16 ongoing trials including five Phase 3 studies. While the disclosure concerns clinical development progress rather than a discrete event like an approval, acquisition, or financial result, it represents material operational and strategic progress in the company's core oncology development program that would affect a reasonable investor's assessment of pipeline momentum and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:37:39.162477+00:00","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-20"}]}